GU Cancers 2019 | Early use of radium-223 is beneficial for asymptomatic mCRPC

Axel Heidenreich

Axel Heidenreich, MD, from the University of Cologne, Cologne, Germany, discusses a recent Phase III study (NCT01618370) by his group on the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC). Prof. Heidenreich shares his views on how using radium-223 earlier in the disease course, when patients are asymptomatic or have not yet developed severe symptoms, which could increase the overall survival benefit in mCRPC patients. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video